Shares in Diamyd Medical AB dropped 30 percent Tuesday on news that its gene therapy treatment for cancer pain missed the primary endpoint in a Phase II placebo-controlled trial.
Shares in Diamyd Medical AB dropped 30 percent Tuesday on news that its gene therapy treatment for cancer pain missed the primary endpoint in a Phase II placebo-controlled trial.
Shares in Biotie Therapies Oyj dropped nearly 10 percent Tuesday on news that Roche Holding AG decided not to exercise an option on its selective serotonin (5-hydroxytryptamine) receptor subtype 6 (5-HT6) antagonist SYN-120.
New data from an open-label Phase II extension study prompted Ablynx NV to claim Monday that its tumor necrosis factor-alpha (TNF-alpha) inhibitor ozoralizumab (ATN-103) was back in the game.
Shares in Biotie Therapies Oyj dropped nearly 10 percent Tuesday on news that Roche Holding AG decided not to exercise an option on its selective serotonin (5-hydroxytryptamine) receptor subtype 6 (5-HT6) antagonist SYN-120.
New data from an open-label Phase II extension study prompted Ablynx NV to claim Monday that its tumor necrosis factor alpha (TNF-alpha) inhibitor ozoralizumab (ATN-103) was back in the game.
Despite widespread protests, including a visit from a delegation to its global headquarters in Darmstadt, Germany, and a one-day work stoppage last week, Merck KgaA is proceeding with its original plan to shutter the Geneva headquarters of its Merck Serono division and to transfer all R&D out of Switzerland.
Despite widespread protests, including a visit from a delegation to its global headquarters in Darmstadt, Germany, and a one-day work stoppage last week, Merck KgaA is proceeding with its original plan to shutter the Geneva headquarters of its Merck Serono division and to transfer all R&D out of Switzerland.
Genentech, a member of the Roche Group, exhibited its evident enthusiasm for AC Immune SA's pipeline of antibodies in development for Alzheimer's disease, by in-licensing the company's preclinical tau-targeting program in a deal potentially worth upward of CHF400 million (US$421 million) in up-front plus research, development and sales-associated milestone payments.
Newron Pharmaceuticals SpA is taking over NeuroNova AB in a stock-based deal valued at €15.4 million (US$19.4 million), which will add two clinical-stage programs to its pipeline of drugs for neurodegenerative disease and €16 million in fresh funding.
